Oklahoma Specialized Center of Research in SLE

描述(由申请人提供)：俄克拉荷马医学研究基金会建议成立一个系统性红斑狼疮的专门研究中心(SCOR)，该中心将专注于了解自身抗体在系统性红斑狼疮中的作用。该中心的首要目标将是将风湿病的临床研究与整个校园的基础科学研究人员整合在一起，从而加强该州的基础科学研究和以患者为中心的研究。莫里斯·赖克林博士是主任，他为这个新的综合项目带来了杰出的职业生涯价值的风湿病研究活动。简而言之，这个SCOR有五名关键调查人员、五名合作研究人员(州内)、五名合作研究人员(州外)、九名额外的关节炎调查人员、十四名基础科学调查人员、一名数据和分析核心主任、咨询委员会和一批兼职教员、博士后研究员、临床研究员、医学博士研究生和研究生。 这一建议的关键项目包括了解SLE自身免疫反应如何启动以及自身抗体如何导致发病机制的各种方法。该SCOR的主要项目将集中于了解自身抗体与症状和SLE疾病发病相关的发展，探索自身抗体在血脂异常和加速心脏病发展中的作用，评估B细胞耐受在狼疮自身抗体积累中的基础作用，识别这些异常自身免疫反应的潜在病因，并评估严重血清学和临床SLE表型的遗传易感性。数据和分析核心以及行政核心将为每个单独的项目提供支持。 俄克拉荷马州SLE SCOR的主要目标有四个。首先，SCOR将通过支持上述研究项目，通过基础和临床科学的整合，加强寻找SLE关键病因的研究。第二，生物统计学/研究设计问题将被纳入所有正在进行的风湿病研究中，以提高目前的研究活动水平。第三，关键的独特患者资源将由几个项目共享。最后，SCOR将提供一个多学科的结构和资源，通过涉及心血管生物学、狼疮遗传学、炎症、凝血、分子生物学、免疫生物学、免疫遗传学、临床药理学和蛋白质研究的强大基础科学家的影响，加强当前的临床风湿病研究。

DESCRIPTION (provided by applicant): The Oklahoma Medical Research Foundation proposes a Specialized Center of Research (SCOR) in systemic lupus erythematosus which will focus on understanding the roles of autoantibodies in SLE. The overarching goal of this center will be to integrate clinical rheumatic disease research with basic science investigators from throughout campus thereby strengthening basic science and patient oriented research in this state. Dr. Morris Reichlin is the Director, and he brings a distinguished career's worth of rheumatic disease research activities to this new integrated program. Briefly, this SCOR has five key investigators, five collaborating investigators (in-state), five collaborating investigators (out-of-state), nine additional arthritis investigators, fourteen basic science investigators, a Data and Analysis Core Director, Advisory Committee and a host of adjunct faculty, post-doctoral fellows, clinical fellows, MD-PhD students and graduate students. The key projects for this proposal include various approaches to understand how autoimmune responses start in SLE and how autoantibodies could lead to pathogenesis. The major projects in this SCOR will focus on understanding the development of autoantibodies with regards to symptom and SLE disease onset, exploring the role of autoantibodies in the development of dyslipidemias and accelerated cardiac disease, evaluating the basic role of B cell tolerance in the accrual of lupus autoantibodies, identifying potential etiologic triggers of these aberrant autoimmune responses and assessing the genetic predisposition to a severe serological and clinical SLE phenotype. A Data and Analysis Core and Administrative Core will support each of these individual projects. The primary Oklahoma SLE SCOR objectives are fourfold. First, this SCOR will strengthen research through integration of basic and clinical science in finding key etiological factors for SLE by supporting the above mentioned research projects. Second, biostatistical/research design issues will be incorporated into all ongoing rheumatic disease research in order to raise the current level of research activity. Third, key unique patient resources will be shared by several of the projects. Finally, this SCOR will provide a multidisciplinary structure and resources to strengthen current clinical rheumatic disease research through the influence of strong basic scientists involved in cardiovascular biology, lupus genetics, inflammation, coagulation, molecular biology, immunobiology, immunogenetics, clinical pharmacology and protein studies.